Global & Disaster Medicine

Archive for the ‘Influenza’ Category

President Donald J. Trump Is Working to Modernize and Improve Influenza Vaccines

White House

MODERNIZING INFLUENZA VACCINES: President Donald J. Trump is safeguarding public health by helping ensure Americans have access to effective influenza vaccines. 

 

  • Today, President Trump signed an executive order to modernize influenza vaccines and help protect more Americans through vaccination.
  • At President Trump’s direction, the Administration will work to promote new technologies to improve vaccine manufacturing and effectiveness.
    • This will reduce reliance on more time-consuming, egg-based vaccine production.
    • Improving the speed of production will enable experts to better match vaccines to actively circulating viruses, an important piece of making the vaccines more effective.
    • The Administration will advance the development of new, more effective vaccines.
  • The Trump Administration will also work to increase Americans’ access to vaccines by reducing barriers to seasonal flu vaccine services.
  • To help put these objectives into action, President Trump is establishing a task force to identify policy priorities and monitor progress.

PROTECTING LIVES THROUGH PREVENTION: Influenza vaccines are vitally important to disease prevention, yet current production methods need to be improved.

  • Influenza vaccines are the best way to save lives, reduce the illness severity, and prevent influenza infections in the first place.
    • During the 2017–2018 flu season, influenza vaccinations prevented up to 7.1 million illnesses, 3.7 million medical visits, and 109,000 hospitalizations.
    • A Centers for Disease Control and Prevention study found that vaccines prevented more than 40,000 flu-associated deaths over a nine-year period.
  • It is especially important to be able to rapidly produce well-matched influenza vaccines using scalable technologies in the event of a future influenza pandemic.
  • Despite their important role in safeguarding the health of the American people, influenza vaccines are currently produced using more time-consuming, egg-based technology.
    • More rapid non-egg-based production methods would give experts more time to select the most relevant strains.

PROMOTING PUBLIC HEALTH: Improving the influenza vaccine is part of President Trump’s longstanding effort to combat public health threats and promote quality care for all Americans.

  • President Trump has released a National Biodefense Strategy and a Global Health Security Strategy to help combat biological threats and pandemics.
  • President Trump has made it a priority to increase the quality and accessibility of care for American patients.
    • This year, the President launched a kidney health initiative to help prevent kidney failure, improve treatment options, and expand access to life-saving transplants.
    • The Trump Administration is working to encourage new, innovative approaches to treating childhood cancer.
    • President Trump launched an initiative to end the HIV/AIDS epidemic in America over the next decade.
    • The Administration is supporting research on new treatments for opioid addiction.

Rubbing hands with ethanol-based sanitizers may not be effective hand hygiene after all.

ASM

“……the researchers from the Kyoto Profectural University of Medicine found that ethanol-based disinfectants, or hand sanitizers, would have be in contact for at least 4 minutes with the influenza A virus before killing it, a much longer duration than typical use. After 2 minutes of use, the virus was still active...….”

Ryohei Hirose, Takaaki Nakaya, Yuji Naito, Tomo Daidoji, Risa Bandou, Ken Inoue, Osamu Dohi, Naohisa Yoshida, Hideyuki Konishi, Yoshito Itoh
“…….If there is insufficient time before treating the next patient (i.e., if the infectious mucus is not completely dry), medical staff should be aware that effectiveness of AHR (rubbing) is reduced. Since AHW is effective against both dry and nondry infectious mucus, AHW (washing) should be adopted to compensate for these weaknesses of AHR…….”

Baloxavir showed broad-spectrum in vitro replication inhibition of 4 types of influenza viruses

Mishin VP, Patel MC, Chesnokov A, De La Cruz J, Nguyen HT, Lollis L, et al. Susceptibility of influenza A, B, C, and D viruses to baloxavir. Emerg Infect Dis. 2019 Oct [date cited]. https://doi.org/10.3201/eid2510.190607

“…….Baloxavir displayed broad antiviral activity against diverse influenza viruses, including all 4 types and animal-origin influenza A viruses with pandemic potential. Our findings suggest that baloxavir might offer the first therapeutic option against influenza C virus infections. Further studies are needed to provide comprehensive assessment of baloxavir susceptibility by using a large panel of representative influenza C viruses. Ongoing monitoring of baloxavir susceptibility of emerging avian and swine influenza A viruses with pandemic potential is needed to inform clinical management and public health preparedness efforts...…”


2018-2019 Influenza Season Week 20 ending May 18, 2019: Influenza activity remained low in United States and was similar to last week.

CDC

national levels of ILI and ARI

INFLUENZA Virus Isolated

Click on image to launch interactive tool

 


2018-2019 Influenza Season Week 19 ending May 11, 2019: Influenza activity continues to decrease in the United States.

CDC

national levels of ILI and ARI

INFLUENZA Virus Isolated

Click on image to launch interactive tool

 


CDC: 2018-2019 U.S. Flu Season: Preliminary Burden Estimates

37.2 million – 42.7 million
flu illnesses

person coughing icon
17.2 million – 20 million
flu medical visits

524,000 – 637,000
flu hospitalizations

36,100 – 59,600
flu deaths


2018-2019 Influenza Season Week 17 ending April 27, 2019

national levels of ILI and ARI

INFLUENZA Virus Isolated

Click on image to launch interactive tool


CDC: Influenza activity continues to decrease in the United States.

CDC

national levels of ILI and ARI

INFLUENZA Virus Isolated

Click on image to launch interactive tool


2018-2019 Influenza Season Week 14 ending April 6, 2019

CDC

national levels of ILI and ARI

INFLUENZA Virus Isolated

Click on image to launch interactive tool


2018-2019 U.S. Flu Season: Preliminary Burden Estimates

CDC

person coughing icon

34.9 million – 40.1 million
flu illnesses

16.1 million – 18.8 million
flu medical visits

482,000 – 585,000
flu hospitalizations

32,900 – 54,800
flu deaths

Preliminary Cumulative Estimates of Hospitalizations in the U.S. 2018-2019 Flu Season


Categories

Recent Posts

Archives

Admin